新股消息 | 妍美生物港股IPO招股书失效

Core Viewpoint - Yangmei Biotechnology (Chengdu) Co., Ltd. has seen its Hong Kong IPO application expire after six months, indicating potential challenges in the market for biotech companies [1] Company Overview - Yangmei Biotechnology was established in 2016 and focuses on the research, production, and commercialization of regenerative medical devices and specialized medical foods [1] - The company is dedicated to the development, transformation, and application of regenerative medical materials, as well as the research of specific full-nutrition formula foods [1] Technological Capabilities - Yangmei Biotechnology has been actively advancing cutting-edge technology research and exploring innovative application scenarios in the field of regenerative medical materials [1] - The company has accumulated key technologies in the research, modification, preparation of polymer materials, regenerative biomaterials, and microsphere development [1] - Yangmei Biotechnology possesses the capability to transform regenerative medical material technology into mature products that meet market demands [1] Product Portfolio - As a technology platform enterprise for regenerative medical materials, Yangmei Biotechnology has a strong product portfolio that includes two main product lines: regenerative medical material injectables and medical dressings and patches made from regenerative medical materials [1]